Table 2.
Clinical measurements available for CF study participants.
| Within CF | All | 0–10 years | >10 –18 years |
|---|---|---|---|
| clinical analysis (n = 19) | 19 | 8 | 11 |
| Age, (years, median [IQR]) | 11.2 | 7.6 | 13.7 |
| Female, n (%) | 10 (52.6%) | 3 (37.5%) | 8 (63.6%) |
| Pancreatic Sufficient | 2 | 1 | 1 |
| Pancreatic Insufficient | 17 | 7 | 10 |
| Genotype F508del homozygous F508del heterozygous Other |
10 4 5 |
4 4 0 |
6 0 5 |
| HAZ (SD) | 0.26 (1.2) | 0.28 (0.58) | 0.24 (1.49) |
| WAZ (SD) | 0.44 (0.94) | 0.40 (0.52) | 0.47 (1.2) |
| BMIZ (SD) | 0.48 (0.70) | 0.30 (0.60) | 0.62 (0.76) |
| FEV1 | 2.06 | 1.45 | 2.5 |
| FEV1% pred | 98.9 | 104.1 | 95.0 |
| FVC | 2.50 | 1.70 | 3.08 |
| FVC% pred | 105.0 | 110.0 | 101.4 |
| Pseudomonas aeruginosa infections (mean) | 0.79 | 0.63 | 0.91 |
| Detected pathogens of interest (mean) | 0.74 | 0.13 | 1.18 |
| CFPE last 3 years (mean) | 1.16 | 0.88 | 1.40 |